Elad leads the commercialisation of Navigate Precision Oncology, a project to enhance the personalised treatment of cancer patients. He has a long standing interest in complex biology, especially the physiological relevance of 3D cell cultures. In the MRC PPU, Elad is expanding the utility of the technology to stem cell-based applications.